Stratatech Closes $3-Million Funding Round to Advance Clinical Trial

Published: May 04, 2010

MADISON, Wis.--(BUSINESS WIRE)--Stratatech Corp., a regenerative medicine company focused on the commercialization of cell-based, tissue-engineered skin substitute products, today announced that it has closed a $3.0-million round of funding comprised of convertible notes. The funding was secured from current investors in the company. The proceeds will be used to advance the clinical trial of the company’s StrataGraft® living human skin substitute tissue. The company expects to begin Phase IIb of the trial during the second half of 2010.

Back to news